Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers

Currently, no disease modifying therapies (DMTs) have been approved for use in dementia with Lewy bodies (DLB). Clinical trials face difficulties due to the clinical and neuropathological heterogeneity of the condition with a diverse array of neuropathogenic mechanisms contributing to the clinical p...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibson, Lucy L., Abdelnour, Carla, Chong, Joyce, Ballard, Clive, Aarsland, Dag
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
NEUROIMAGING: Edited by Massimo Filippi
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328538/
https://www.ncbi.nlm.nih.gov/pubmed/37387459
http://dx.doi.org/10.1097/WCO.0000000000001173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328538/
https://www.ncbi.nlm.nih.gov/pubmed/37387459
http://dx.doi.org/10.1097/WCO.0000000000001173

Ejemplares similares